Evaluation of influenza virus antiviral susceptibility testing in Europe: Results from the first external quality assessment exercise

Journal of Clinical Virology

Volumn 56, Issue 3, 2013, Pages 296-302

  Thompson, C I ^a   Lackenby, A ^a   Daniels, R S ^b   McCauley, J W ^b   Pereyaslov, D ^c   Broberg, E K ^d   Meijer, A ^e   Zambon, M C ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^d EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Antiviral; External quality assessment; Influenza; Neuraminidase inhibitors; Proficiency testing

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL SUSCEPTIBILITY TESTING; ARTICLE; EUROPE; GENOTYPE; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 84872847533     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.11.005     Document Type: Article

References (23)

1. Kitler M.E., Gavinio P., Lavanchy D. Influenza and the work of the World Health Organization. Vaccine 2002, 20(Suppl. 2):S5-S14.
2. Meijer A., Valette M., Manuguerra J.-C., Pérez-Breña P., Paget J., Brown C., et al. Implementation of the community network of reference laboratories for human influenza in Europe. J Clin Virol 2005, 34(2):87-96.
3. Meijer A., Brown C., Hungnes O., Schweiger B., Valette M., van der Werf S., et al. Programme of the community network of reference laboratories for human influenza to improve influenza surveillance in Europe. Vaccine 2006, 24(44-46):6717-6723.
4. Valette M., Aymard M. Quality control assessment of influenza and RSV testing in Europe: 2000-01 season. Euro Surveill 2002, 7(11):161-165.
5. Meijer A., Lackenby A., Hay A., Zambon M. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro Surveill 2007, 12(4):E3-E4.
6. Zambon M., Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antivir Res 2001, 49:147-156.
7. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009, 15(4):552-560.
8. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008, 13(5). pii=8026.
9. Calatayud L., Lackenby A., Reynolds A., McMenamin J., Phin N.F., Zambon M., et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg Infect Dis 2011, 17(10):1807-1815.
10. Hurt A.C., Hardie K., Wilson N.J., Deng Y.-M., Osbourn M., Gehrig N., et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011, 365(26):2541-2542.
11. World Health Organisation. Summary of influenza antiviral susceptibility surveillance findings, September 2010 - March 2011. 6 June 2011. Available from: . http://www.who.int/influenza/gisrs_laboratory/updates/antiviral_susceptibility/en/index.html.
12. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003, 47:2264-2272.
13. Bright R.A., Medina M.-J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366(9492):1175-1181.
14. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007, 196(2):249-257.
15. Lackenby A., Democratis J., Siqueira M.M., Zambon M.C. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther 2008, 13(6):809-820.
16. Lackenby A., Thompson C.I., Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008, 21(6):626-638.
17. Jonges M., Liu W.M., van der Vries E., Jacobi R., Pronk I., Boog C., et al. Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. J Clin Microbiol 2010, 48(3):928-940.
18. Potier M., Mameli L., Belisle M., Dallaire L., Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Anal Biochem 1979, 94:287-296.
19. Buxton R.C., Edwards B., Juo R.R., Voyta J.C., Tisdale M., Bethell R.C. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000, 280(2):291-300.
20. Sugaya N., Mitamura K., Yamazaki M., Tamura D., Ichikawa M., Kimura K., et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007, 44(2):197-202.
21. Gubareva L.V., Trujillo A.A., Okomo-Adhiambo M., Mishin V.P., Deyde V.M., Sleeman K., et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010, 15:1151-1159.
22. Hurt A.C., Chotpitayasunondh T., Cox N.J., Daniels R., Fry A.M., Gubareva L.V., et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012, 12(3):240-248.
23. World Health Organisation Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012, 87(39):369-374.